B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors

Zongliang Zhang,1,5 Caiying Jiang,2,5 Zhiyong Liu,3,5 Meijia Yang,1 Xin Tang,3 Yueling Wang,3 Meijun Zheng,4 Jianhan Huang,3 Kunhong Zhong,1 Shasha Zhao,1 Mei Tang,1 Tingyue Zhou,1 Hui Yang,4 Gang Guo,1 Liangxue Zhou,3 Jianguo Xu,3 and Aiping Tong1

1State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China; 2Life Science and Clinical Research Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Province, China; 3Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China; 4Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China

Recently, B7-H3 was frequently reported to be overexpressed in various cancer types and has been suggested to be a promising target for cancer immunotherapy. In the present study, we analyzed the mRNA expression of B7-H3 in The Cancer Genome Atlas (TCGA) database and validated its expression across multiple cancer types. We then generated a novel B7-H3-targeted chimeric antigen receptor (CAR) and tested its antitumor activity both in vitro and in vivo. The B7-H3 expression heterogeneity and variation were frequent. Moderate or even high expression levels of B7-H3 were also observed in some tumor-adjacent tissues, but the staining intensity was weaker than that in tumor tissues. B7-H3 expression was absent or very low in normal tissues and organs. Flow cytometry indicated that the mean expression level of B7-H3 in eight bone marrow specimens from patients with acute myeloid leukemia (AML) was 57.2% (range 38.8–80.4). Furthermore, we showed that the B7-H3-targeted CAR-T cells exhibited significant antitumor activity against AML and melanoma in vitro and in xenograft mouse models. In conclusion, although B7-H3 represents a promising pan-cancer target, and B7-H3-redirected CAR-T cells can effectively control tumor growth, the expression heterogeneity and variation have to be carefully considered in translating B7-H3-targeted CAR-T cell therapy into clinical practice.

INTRODUCTION

Adoptive cell therapy (ACT) is considered to be one of the most effective immunotherapy methods for cancer treatment. One of the main ACT approaches is to use T cells engineered with chimeric antigen receptors (CARs), also known as CAR-T cells.1 CARs are recombinant receptors comprising an extracellular, antigen-specific, single-chain variable fragment (scFv) fused with intracellular T cell-activating and -costimulatory signaling domains, which provide both antigen-binding sites and T cell-activating functions. CARs can recognize tumor antigens specifically, trigger T cell activation in a non-major histocompatibility complex (MHC)-restricted manner, and initiate an extraordinary anti-tumor response.3 Cluster of differentiation (CD)19-targeting CAR-T cell therapy has been successful in the treatment of refractory/relapsed B cell malignancies, and the therapy was approved by the US Food and Drug Administration (FDA).

Despite the success of the use of CAR-T cells in the treatment of hematological tumors, their role in treating solid tumors is limited.4 For hematological malignancies, lineage markers, such as the B cell marker CD19, can be targeted without serious complications caused by depletion of normal CD19+ B cells. However, when treating solid cancers with engineered T cells, the identification of truly tumor-specific surface targets remains a major barrier. Targeting molecules expressed by both tumor and normal cells can cause life-threatening toxicity, as observed in clinical trials with CAR-T cells targeting human epidermal growth factor receptor 2 (HER2) because of the recognition of cognate antigen on the lung epithelium.7

B7-H3 (CD276) is a type I transmembrane protein that belongs to the B7 family.9 Although B7-H3 was originally reported as a positive costimulator of T cells in humans,9 increasing evidence suggests that it may be a negative regulator.8–10 So far, the receptor for B7-H3 was
Overexpression of B7-H3 has been found in a variety of human cancers, including lung adenocarcinoma, craniopharyngioma, neuroblastoma, glioma, ovarian cancer, pancreatic cancer, and acute myeloid leukemia (AML), whereas its expression is absent or low in normal tissues. Although the precise role of B7-H3 in immune regulation and cancer genesis remains unclear, there is no doubt that overexpression of B7-H3 constitutes an attractive biomarker and target for multiple cancer immunotherapy approaches. Several B7-H3-directed therapeutic agents have been undertaken in clinical trials. Enoblituzumab, an Fc-optimized monoclonal antibody (mAb) against B7-H3, was evaluated in a phase I clinical study in combination with an anti-programmed death 1 (PD-1) mAb in patients with B7-H3-expressing solid tumors (ClinicalTrials.gov: NCT02475213). Radiolabeled 8H9, another B7-H3-targeting antibody, has also been evaluated in a phase I trial for the treatment of brain and central nervous system tumors, neuroblastoma, and carcinoma (ClinicalTrials.gov: NCT00089245). Notably, last year, the FDA placed a partial hold on two clinical studies of MGD009, a bispecific antibody targeting B7-H3 and CD3, developed by MacroGenics, because of liver toxicity events in the monotherapy trial, including reversible elevation of transaminase levels with or without concurrent elevation of bilirubin level.

Although the FDA lifted the partial clinical hold after 1 month, on-target, off-tumor toxicity should be considered when developing B7-H3-targeted therapeutics. More recently, we and others have found that B7-H3 is highly and homogeneously expressed on some pediatric cancers, such as Ewing sarcoma, rhabdomyosarcoma, Wilms tumor, and neuroblastoma, as well as brain cancers, such as medulloblastoma and glioblastoma. It has also been reported that B7-H3-targeting CAR-T cells mediate significant anti-tumor effects in preclinical models of these cancer types.

The aims of the present study were the following: (1) to evaluate whether B7-H3 is a high-value target for CAR-T treatment of other cancer types in addition to pediatric tumors and brain cancers and (2) to develop a novel, B7-H3-specific CAR and evaluate its anti-tumor effects in preclinical cancer models.

**RESULTS**

**Analysis of B7-H3 Expression in The Cancer Genome Atlas (TCGA) Database**

The mRNA expression levels of CD276 were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) web server. Our analysis included the RNA sequencing expression data for 9,433 tumors and 5,540 normal samples from TCGA and the Genotype-Tissue Expression (GTEx) projects. As shown in Figure S1, compared with the expression in normal tissues, B7-H3 expression was significantly higher in 15 of 31 tumor types; ten of the 15 tumor types with B7-H3 overexpression were selected, and their details are shown in Figure 1A. The correlation between B7-H3 expression and survival was also calculated using TCGA datasets. As a result, higher B7-H3 expression predicted a shorter life expectancy in patients with low-grade glioma (LGG).
B7-H3 Expression in Multiple Human Tissues

We performed immunohistochemical (IHC) staining to detect B7-H3 expression in tissue microarrays, including tumor, tumor-adjacent, and normal tissues. Of 209 tumor samples, 18% showed strong staining, 21% moderate staining, and 27% low but detectable staining. A complete description of the IHC results is provided in Tables S1, S2, and S3. B7-H3 was overexpressed across multiple cancer types, including 88% of bladder urothelial carcinoma (BLCA), 60% of breast invasive carcinoma (BRCA), 89% of esophageal carcinoma (ESCA), 63% of stomach adenocarcinoma (STAD), 80% of liver hepatocellular carcinoma (LIHC), 76% of lung adenocarcinoma (LUAD), 80% of skin squamous cell carcinoma (SSCC), and 61% of pancreatic adenocarcinoma (PAAD). Importantly, we found homogeneous overexpression of B7-H3 in only a small percentage of samples of liver cancer, breast cancer, cervical cancer, bladder cancer, and carcinoma, whereas its expression in other cancer types was highly heterogeneous. Representative images are shown in Figure 2A and Figure S3.

Notably, B7-H3 was detected with moderate or even high expression levels in 84/209 (40%) tumor-adjacent tissues (TATs) for cancers, such as skin, lung, liver, cervical, ovary, and prostate, but the staining was much weaker than that in the tumor tissues (Table S2). In some TATs, such as lung and colon TATs, B7-H3 stained positively, mainly in stromal cells (Figure 2B). We also detected the expression of B7-H3 in 173 human normal tissues. B7-H3 expression was absent or weak in normal tissues, and only three (25%) liver samples, one (13%) prostate sample, two (29%) uterus samples, and three (20%) adrenal gland samples had weak to moderate staining (Table S3; Figures 2C and S4).

Generation and Characterization of mAb Against B7-H3

A B7-H3-specific mAb (mAb-J42) was generated using the traditional hybridoma technique. The B7-H3-specific scFv was derived from mAb-J42 and named J42-scFv. The binding of mAb-J42 and J42-scFv-Fc to cell surface-expressed B7-H3 was confirmed by immunofluorescence (IF) staining using HeLa cells that stably express B7-H3-green fluorescent protein (GFP) (Figure 3A). HeLa cells exhibit...
The innate expression of B7-H3 protein. The binding affinity of J42-scFv-Fc to B7-H3 extracellular domain (ECD) recombinant protein was measured using the Biacore X100 instrument (Figure 3B; Table S4). Specific recognition was examined further in knockout of B7-H3 (B7-H3KO) cells. Figure 3C shows the sequencing results for A375 cells, 5 days after transduction with lentivirus carrying B7-H3-targeted gRNA and Cas9. (C) Sequencing results for A375 cells, 1 week after transduction with lentivirus carrying B7-H3-targeted gRNA and Cas9. (D) FACS analysis of B7-H3 expression in A375 and HepG2 cells, 1 week after transduction with lentivirus carrying B7-H3-targeted gRNA and Cas9. (E) IF staining with mAb-J42 in FACS-sorted B7-H3KO A375 and HepG2 cells and in wild type of A375 and HepG2 cells. Scale bars, 20 μm. (F) Expression of B7-H3 in human tumor cell lines and AML patient samples were evaluated by FACS. Cells were incubated with mAb-J42 (red) or its corresponding isotype control (blue).
negative controls. The positive and negative expression of B7-H3 was examined further by IF staining (Figure 4E). The 51Cr-release cytoxic assay was adopted to test the specific lytic function of B7-H3-re-directed CAR-T cells (Figures 4F and S5). B7-H3-re-directed CAR-T cells were cocultured with tumor cells for 4 h, after which, CAR-T cells efficiently lysed B7-H3-positive A375 and MV4-11 cells; by contrast, no significant response was observed in B7-H3-negative Raji cells and PBMCs. These cells were cocultured at an effector:target (E:T) ratio of 4:1 for 24 h, and target cell lysis was confirmed by FACS and enzyme-linked immunosorbent assay (ELISA). Representative FACS plots are shown in Figure 5A. A375, Raji, and MV4-11 cells were identified by their B7-H3 expression. The expression of B7-H3 in PBMCs and the cytotoxicity of CAR-T cells against PBMCs were shown in Figure S5.

The secretion of perforin by T cells was also analyzed with FACS (Figure 5B). B7-H3-re-directed CAR-T cells mediated tumor cell killing, and perforin secretion increased in B7-H3-positive cells but not in B7-H3-negative cells. CAR-T cells caused 95% cell death in MV4-11 AML cells. The percentages of residual tumor cells were estimated from the FACS data, and the results are presented in Figure 5C. Increased secretion of tumor necrosis factor α (TNF-α), interleukin (IL)-2, and interferon γ (IFN-γ) was observed in B7-H3-re-directed CAR-T cells cocultured with B7-H3-positive tumor cells (A375, MV4-11, HepG2, and U937) but not in cells cocultured with B7-H3-negative Raji cells (Figures 5D–5F).

Anti-Tumor Effects of B7-H3-Redirected CAR-T Cells in Vivo
To test the efficacy of B7-H3-re-directed CAR-T cells against tumors in vivo, we adopted two xenograft tumor models of hematological and solid tumors. In the solid tumor model, we injected 2 × 10^6 A375-FFLuc cells subcutaneously into the right flank of NOD-Prkdck−/−IL2rgtm1Smoc (M-NSG) mice. Eight days after tumor inoculation, mice were injected intravenously with a single dose of 5 × 10^6 B7-H3-re-directed CAR-T cells, CD19 CAR-T cells, or phosphate-buffered saline (PBS) (Figure 6A). Tumor burden was monitored by in vivo bioluminescence imaging (BLI) every 10 days beginning on day 7, and tumor size was measured using a vernier caliper every 3–4 days. As shown in Figures 6B and 6C, B7-H3-re-directed CAR-T cells mediated significant regression of xenografts.

In the hematological tumor model, a total of 2 × 10^6 MV411-FFLuc cells were implanted into M-NSG mice via tail-vein injection. Eight days later, when the bioluminescence of the tumors could be detected, mice were infused with 5 × 10^6 B7-H3-re-directed CAR-T cells, mock T cells, or PBS via tail-vein injection (Figure 6D). Tumor progression was monitored by BLI every 8 days beginning on day 7 (Figure 6E). Mice in the control group showed rapid progression of leukemia, and most died around 25 days after tumor inoculation. By contrast, almost complete regression of leukemia was observed in mice treated
with B7-H3-redirected CAR-T cells, as evidenced by BLI. This led to a significant survival advantage compared with mice in the other two groups (Figure 6F). We also examined the B7-H3-positive leukemia cells in peripheral blood using FACS, 15 days after tumor inoculation. Consistent with the BLI results, mice treated with B7-H3-redirected CAR-T cells exhibited significantly decreased tumor burden compared with mock T- or PBS-treated mice (Figure 6G).

DISCUSSION

Unprecedented success has been achieved in B cell malignancies treated by the adoptive transfer of T cells redirected with a CAR specific for CD19. However, in solid tumors, most of the reported tumor markers are often heterogeneous within tumors, and these markers are expressed in some normal tissues, which lead to limited therapeutic effects or life-threatening toxicity. Epidermal growth factor receptor (EGFR)vIII, a mutant EGFR, is a tumor-specific marker for glioblastoma, but its heterogeneous expression limits the therapeutic efficacy of EGFRvIII CAR-T cells. Treatment with CAR-T cells targeting HER2 caused a patient death because of the recognition of low levels of HER2 on lung epithelial cells. B7-H3 expression was absent or weak in normal tissues but could be detected at a moderate or even high expression level in some TATs, such as those associated with skin, lung, cervical, and prostate cancers. Previous work has shown that B7-H3 expression can be induced in normal tissue in response to inflammation. Thus, it will be important in the future to explore its upregulation mechanisms in TATs and to develop more efficient and safer targeted therapy.

A previous study has shown that B7-H3-targeted CAR-T cells have limited activity against K562 cells, a xenograft erythromyeloid leukemia line, because of the lower B7-H3 antigen density on the K562 cell membrane. We examined several cell lines of hematological malignancies and found that MV4-11, an AML cell line, had the highest expression level of B7-H3. With the use of MV4-11 as a model, we found that B7-H3-targeted CAR-T cells displayed significant antitumor activity in vitro and in vivo and caused regression of established cancer and prolonged survival in xenograft tumor models. These findings suggest that the target antigen density is also a key factor for recognition and killing by CAR-T cells.

Recently, B7-H3 has emerged as an attractive target for immunotherapy, because it is highly expressed across multiple tumor types but exhibits restricted expression in normal tissues. In this study, we performed large-scale screening of the expression of B7-H3 using TCGA data and IHC. We found homogeneous overexpression of B7-H3 only in a small percentage of samples of liver, breast, cervical, and bladder cancers and SCC, whereas its expression in other cancer types was highly heterogeneous. Notably, the mRNA expression of B7-H3 was ubiquitous in almost all of the normal TATs from TCGA database. In IHC, B7-H3 expression was absent or weak in normal tissues but could be detected at a moderate or even high expression level in some TATs, such as those associated with skin, lung, cervical, ovary, and prostate cancers. Previous work has shown that B7-H3 expression can be induced in normal tissue in response to inflammation. Thus, it will be important in the future to explore its upregulation mechanisms in TATs and to develop more efficient and safer targeted therapy.
Recently, two posters from the American Society of Hematology Annual Meeting reported that B7-H3 is highly expressed in a substantial fraction of AML patients and that adoptive transfer of B7-H3-targeted CARs may be an effective treatment option for AML patients with B7-H3 overexpression. The authors of these posters also reported variable expression patterns of B7-H3 in patients with AML and suggested that it may be necessary to develop a dual-targeting approach, such as combining B7-H3 with a second AML surface antigen.\(^{23,24}\)

In the present study, using IHC, we observed wide regional variation of B7-H3 expression within and across the tumor tissues. B7-H3 was previously suggested to be a valuable CAR-T target for pancreatic ductal adenocarcinoma, ovarian cancer, and myelogenous leukemia.\(^{13}\) Here, we also observed positive B7-H3 staining in pancreatic ductal adenocarcinoma and ovarian cancer, but the expression was highly heterogeneous. Antigen heterogeneity is one of the main reasons for failure of CAR-T cell therapy.\(^{13}\) It may be necessary to examine the B7-H3 expression status in surgical specimens before starting targeted therapy. On the other hand, to address the issue of antigenic heterogeneity, the use of bispecific CAR, such as CD19/CD22-bispecific CAR-T cells, has been proposed for the treatment of acute lymphoblastic leukemia (ClinicalTrials.gov: NCT03919526) to overcome the risk of antigen-escape relapse and to improve the duration of the clinical benefit. Thus, the combination of B7-H3 with another tumor antigen in the CAR design may be necessary.

**METHODS**

**Mice**

6- to 8-week-old immunodeficient M-NSG female mice were purchased from the Model Animal Resource Information Platform of Nanjing University (China). Mice were maintained under specific pathogen-free conditions, and all procedures met the requirements of the National Institutes of Health and Institutional Animal Care and Use Committee. The animal experiments were approved by the West China Hospital of Sichuan University Biomedical Ethics Committee (ethical approval document: 2018-061).

**Human Tissue Microarray and Clinical Specimens**

IHC was performed using human tissue microarrays purchased from Xi’an Alenabio and Shanghai Outdo Biotech of China. Bone marrow aspirates from patients with monocytic/myelomonocytic AML were obtained and subjected to flow cytometry analysis. This study was approved by the West China Hospital of Sichuan University Biomedical Ethics Committee (ethical approval document: 2018-061), and the participating patients provided written, informed consent.

**Cell Lines and Culture Conditions**

All tumor cell lines used in this study were originally purchased from the American Type Culture Collection (ATCC). A375-FFluc and MV4-11-FFluc cell lines were produced by transducing a lentiviral vector.
vector that encoded the luciferase reporter gene into the original cell lines. All cells were maintained in Dulbecco’s modified Eagle’s medium or RPMI-1640 (both from Gibco), supplemented with 10% fetal bovine serum and 2 mM l-glutamine (Invitrogen).

**Expression of B7-H3 in Tumors from TCGA Database**
The expression of B7-H3 in 9,433 tumors and 5,540 normal samples from TCGA database and the GTEx project, including 31 different tumor subtypes, was analyzed using the online web server GEPIA (http://gepia.cancer-pku.cn). Data were downloaded, filtered for primary tumors, log2 transformed, and analyzed using R.

**Immunohistochemistry**
Tissue samples were stained for B7-H3 using a commercial mAb (clone D9M2L; Cell Signaling Technology). All procedures followed the manufacturer’s protocol. In brief, tissue sections were incubated at 65°C for 1 h to retrieve antigenicity, blocked with PBS containing 10% normal goat serum (Boster) for 30 min at room temperature, and then incubated with primary antibody at 4°C overnight. The sections were then incubated with goat anti-rabbit secondary antibodies, and the staining was detected with 3,3'-diaminobenzidine (ZSGB-Bio). The staining intensity was scored using a common four-point scale as follows: no expression (−), <20% positive cells (+, low or weak expression), 20%–50% positive cells (++, moderate expression), and >50% positive cells (+++, high or strong expression).

**Lentivirus Production**
HEK293FT cells were transfected with the target plasmid and two packaging plasmids pSPAX2 and pMD.2G at a ratio of 4:3:2 using polyethylenimine (Sigma). The supernatants were collected at 48 h and 72 h after transfection, filtered with 0.45 μm filters, and concentrated by ultracentrifugation at 15,000 rpm for 2 h. The concentrated lentivirus was resuspended in RPMI-1640 and immediately stored at −80°C for further use.

**Overexpression of B7-H3 in HeLa Cells**
Full-length human B7-H3 (GenBank: NM_001024736) was synthesized by Genewiz and cloned into a lentiviral vector with a GFP tag at the C terminus. HeLa cells were transduced with lentiviral vectors, as described above, and selected using puromycin to generate HeLa–B7-H3–GFP cells.

**Generation of Monoclonal Antibody**
The ECD of B7-H3 was subcloned into a eukaryotic expression vector with Fc and His tags at the C terminus. B7-H3–ECD–Fc fusion protein was produced by transiently transfecting HEK293F cells and purified using protein A and nickel-nitrilotriacetic acid (Ni-NTA) affinity columns, and 8- to 10-week-old female BALB/c mice were immunized with B7-H3–ECD–Fc recombinant protein. Hybridomas were produced by fusion of spleen cells with SP2/0 cells. Hybridomas were screened using an ELISA, IF, and flow cytometry.

KO of B7-H3 in Tumor Cells
A375 and HepG2 cell lines with B7-H3 KO were produced using a CRISPR-Cas9 system. gRNAs were designed using the online server CHOPCHOP (http://chopchop.chbu.uib.no). gRNAs were subcloned into lentiCRISPR version (v;2) (Addgene; #52961). Lentiviral particles were transduced into A375 and HepG2 cells and selected with puromycin. 1 week after transduction, the cells were stained with mAb-J42, and B7-H3-negative cells were sorted using a FACS (BD Biosciences).

**Affinity Determinations Using a Biacore Instrument**
The binding affinity of mAb-J42 and J42-scFv-Fc to B7-H3 recombinant protein was measured using a Biacore X100 instrument with a CM5 sensor chip (GE Healthcare), according to a previously published procedure. Briefly, B7-H3–ECD–His recombinant protein containing the ECD of B7-H3 with a His tag at the C terminus was produced by transiently transfecting HEK293F cells and purified using Ni-NTA affinity columns and size-exclusion chromatography. Fc-tagged J42-scFv was expressed, as mentioned above, for B7-H3–ECD–Fc protein. A rabbit anti-mouse IgG antibody (mouse antibody capture kit; GE Healthcare) was immobilized on CM5 using amine coupling (amine coupling kit; GE Healthcare), mAb-J42 and Fc-tagged J42-scFv were indirectly captured onto the surface, and the B7-H3–ECD–His protein was injected across the chip in a 2-fold dilution series. The equilibrium dissociation constant was obtained by using BIAevaluation 2.0 software.

**Immunofluorescence Staining**
Cells were incubated in 24-well plates under standard cell-culture conditions. After 24 h, the cells were blocked with 1% bovine serum albumin for 30 min, stained with primary antibody (mAb-J42 or J42-scFv-Fc) for 1 h at 4°C, fixed in 4% paraformaldehyde for 15 min, and stained with fluorescein isothiocyanate (FITC)- or Cy3-conjugated secondary antibody (Proteintech) and 4,6-diamidino-2-phenylindole (Beyotime). Images were captured on a confocal microscope (Zeiss 880).

**Flow Cytometry and Antibodies**
B7-H3 expression levels on the surface of human tumor cells were detected using purified mAb-J42 or J42-scFv-Fc. Goat anti-mouse IgG–FITC (Proteintech) was used to label the Fc of mAb-J42. The antibodies used to identify the phenotype of CAR-T cells included CD3-allophycocyanin (APC)-CY7, perforin-APC, CD4-PE, CD8-FITC, TIM3-BV711, and PD-1-BV605 (all purchased from BioLegend). Flow cytometry analysis was performed on a BD Fortessa flow cytometer and analyzed using FlowJo 10.6.0 software.

**T Cell Transduction**
The B7-H3-specific binder J42-scFv was derived from mAb-J42 by coconnection of the variable heavy (VH) and variable light (VL) with a G4S linker. B7-H3-redirected CAR was constructed using a lentiviral vector encoding J42-scFv, CD28 and 4-1BB costimulatory domains, and the CD3-ζ-signaling domain, with the human eukaryotic translation elongation factor 1 alpha (EF1α) as the promoter.
Human peripheral blood mononuclear cells from healthy donors were isolated using density gradient centrifugation and activated by culturing with anti-CD3 mAb (OKT3, 100 ng/mL; BioLegend), CD28 mAb (CD28.2, 100 ng/mL; BioLegend), and recombinant human IL-2 (100 units/mL; Life Science) in X-vivo medium (Lonza), supplemented with 2 mM l-glutamine, 10 mM HEPES, 100 U/mL penicillin, and 100 μg/mL streptomycin. On day 2, activated T cells were transduced with lentivirus particles using hexadimethrine bromide (polybrene) (Sigma) for 12 h and then cultured continuously for 10–14 days. Mock T cells and CD19 CAR-T cells were established under the same conditions, and NT cells were not transduced with lentivirus.

Cytotoxicity Assays
The 51Cr assay was adopted to detect the cytotoxicity of B7-H3-redirected CAR-T cells, as previously described. Briefly, CAR-T cells and tumor cells were labeled with sodium chromate (molecular formula: Na251CrO4) and cocultured at an E:T ratio of 16:1, 8:1, 4:1, and 1:1 for 4 h. The supernatants were collected, and the radioactivity was measured using a gamma counter. The percentage of specific lysis was calculated by the following formula: (test release − spontaneous release)/(maximal release − spontaneous release) × 100.

T Cell Functional Assays
B7-H3-redirected CAR-T cells (4 × 105) and tumor cells (1 × 105) were cocultured in 24-well plates at 37°C without addition of exogenous cytokines. After 24 h, the cells were harvested for flow cytometry analysis. Residual tumor cells and perforin secretion by CAR-T cells were measured by flow cytometry. For ELISA assays, CAR-T cells and tumor cells were cocultured at an E:T ratio of 4:1 at 37°C, without the addition of exogenous cytokines for 12 h, and the supernatant was collected from each coculture. The concentrations of IL-2, TNF-α, and IFN-γ in the supernatant were measured using ELISA kits (BioLegend).

Tumor Models and Treatment
In the solid tumor model, each mouse was injected subcutaneously in the right flank with 2 × 106 A375-FFLuc. On day 7, the mice were randomly divided into three groups, five mice per group. On day 8, the mice were injected intravenously with 5 × 106 B7-H3 CAR-T cells in 200 μL, an equal number of CD19 CAR-T cells, or an equal volume of PBS, respectively. The progress of tumor growth was monitored by measuring the bioluminescence signal and size using a vernier caliper. The tumor volume was calculated as follows: tumor size = (long diameter × short diameter2)/2.

In the hematologic tumor model, 2 × 106 MV4-11-FFLuc leukemia cells were injected into the tail vein. 7 days later, mice were divided into three groups and treated with PBS, 1 × 107 mock T cells, or 1 × 107 B7-H3 CAR-T cells, respectively. To monitor tumor growth, the In Vivo Imaging System (IVIS) (Caliper Life Sciences) was used to record mice bioluminescence imaging. Bioluminescence was activated 10 min after intraperitoneal injection with 150 mg/kg β-luciferin (Beyotime). Living Image software (PerkinElmer) was used to analyze the data.

Data Visualization and Statistical Analysis
The data were visualized on graphs and are presented as mean ± standard deviation (SD). The data were analyzed using GraphPad Prism software v.7.0. For Kaplan–Meier overall survival analysis, a log-rank test was used to compare each of the arms. Student’s t test was used to compare the degree of killing by CAR-T cells and mock T cell products. Tumor growth data were analyzed using two-way analysis of variance (ANOVA). Differences between the means for the numbers of B7-H3-positive leukemia cells in peripheral blood were assessed using one-way ANOVA with Bonferroni’s post-test correction. p < 0.05 was considered to be significant, and the significance levels are represented in the figures as *p < 0.05, **p < 0.01, and ***p < 0.001.

Ethics Approval and Consent to Participate
The project protocol was approved by the Biomedical Ethics Committee of West China Hospital of Sichuan University. The use of primary tumor samples obtained from patients and blood samples from patients or donors was approved by the West China Hospital of Sichuan University Biomedical Ethics Committee (ethical approval document 2018-061). Written, informed consent was obtained from patients and donors.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.omto.2020.03.019.

AUTHOR CONTRIBUTIONS
Z.Z., C.J., and Z.L. performed the experiments, analyzed the data, and wrote the manuscript. C.J., Z.Z., and M.T. performed the hybridoma screening and antibody generation. X.T., Y.W., J.H., M.Y., M.T., and M.Z. participated in the vector construction, sample collection, and animal experiments. K.Z., S.Z., and M.T. participated in the protein purification, CAR-T cell manufacture, and data collection. T.Z. performed the bioinformatics analysis. H.Y., G.G., and L.Z. participated in the design of the experimental work, provided expertise for IHC, and critically reviewed the manuscript. J.X. and A.T. conceived the study, designed the experiments, supervised the research, and wrote the manuscript. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST
C.J., Z.Z., and A.T. have filed patents related to this work. The other authors declare no competing interests.

ACKNOWLEDGMENTS
The authors have obtained consent to publish from the participants to report individual patient data. All authors agree to submit the manuscript for consideration for publication. This work was supported by the National Natural Science Foundation of China (31471286), National Major Scientific and Technological Special Project for Significant New Drugs Development (2019ZX09301-147), 1.3.5 Project for Disciplines of Excellence of the West China Hospital, Sichuan
University (ZYJC18007), and Major Subject of the Science and Technology Department of Sichuan Province (2017SZ0015 and 2019YFS0108).

REFERENCES

1. Rosenberg, S.A., and Restifo, N.P. (2015). Adoptive cell transfer as personalized immunotherapy for cancer. Science 348, 62–68.
2. Sadelain, M., Brentjens, R., and Riviere, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388–398.
3. Johnson, L.A., and June, C.H. (2017). Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 27, 48–58.
4. Mirzadeh, H.R., Rodriguez, A., Shephard, J., Brown, C.E., and Badie, B. (2019). Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Front. Immunol. 10, 780.
5. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and Rosenberg, S.A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851.
6. Prasad, D.V.R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., and Dong, C. (2004). Murine B7-H3 is a negative regulator of T cells. J. Immunol. 173, 2500–2506.
7. Chapoval, A.I., Ni, J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., Dong, H., Sica, G.L., Zhu, G., Tamada, K., and Chen, L. (2001). B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2, 269–274.
8. Veenstra, R.G., Flynn, R., Kreymborg, K., McDonald-Hyman, C., Saha, A., Taylor, P.A., Osborn, M.J., Panoskaltsis-Mortari, A., Schmitt-Graeff, A., Lieberknecht, E., et al. (2015). B7-H3 expression in donor T cells and host cells negatively regulates acute graft versus-host disease lethality. Blood 125, 3335–3346.
9. Steinberger, P., Majdic, O., Derdak, S.V., Pfistershammer, K., Kircherberger, S., Klausner, C., Zlabinger, G., Pickl, W.F., Stockl, J., and Knapp, W. (2004). Molecular characterization of human 41g B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol. 172, 2352–2359.
10. Suh, W.K., Gajewska, B.U., Okada, H., Gronski, M.A., Bertram, E.M., Davicki, W., Duncan, G.S., Bulczynski, J., Pyle, S., Elia, A., et al. (2003). The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4, 899–906.
11. Tang, X., Zhao, S., Zhang, Y., Wang, Y., Zhang, Z., Yang, M., Zhu, Y., Zhang, G., Guo, G., Tong, A., and Zhou, L. (2019). B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma. Mol. Ther. Oncolytics 14, 279–287.
12. Nehama, D., Di Ianni, N., Musio, S., Du, H., Patané, M., Pello, B., Finocchiaro, G., Park, J.H., Dunn, D.E., Edwards, D.S., et al. (2019). B7-H3 redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine 47, 33–43.
13. Du, H., Hirabayashi, K., Ahn, S., Kren, N.P., Montgomery, S.A., Wang, X., Tiruthani, K., Mirlekar, B., Michaud, D., Greene, K., et al. (2019). Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell 35, 221–237.e8.
14. Majzner, R.G., Therrault, J.L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C.W., Rietberg, S.P., Linde, M.H., Xu, P., Rota, C., et al. (2019). CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin. Cancer Res. 25, 2560–2574.
15. Seaman, S., Zhu, Z., Saha, S., Zhang, X.M., Yang, M.Y., Hilton, M.B., Morris, K., Sot, C., Morris, H., Swing, D.A., et al. (2017). Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell 31, 501–515.e8.
16. Guerry, T., Roumier, C., Berthon, C., Rennevillé, A., Preudhomme, C., and Quesnel, B. (2015). B7-H3 protein expression in acute myeloid leukemia. Cancer Med. 4, 1879–1883.
17. Hofmeyer, K.A., Ray, A., and Zang, X. (2008). The contrasting role of B7-H3. Proc. Natl. Acad. Sci. USA 105, 10277–10278.
18. Inamura, K., Yokouchi, Y., Kobayashi, M., Sakakihara, R., Ninomiya, H., Subat, S., Nagano, H., Nomura, K., Okumura, S., Shibutani, T., and Ishikawa, Y. (2017). Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer 103, 44–51.
19. Lee, Y.H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H.J., Jeong, M., Chang, S.H., Kim, B.S., et al. (2017). Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 27, 1034–1045.
20. Kramer, K., Kushner, B.H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzenico, P., Humm, J.I., Xu, H., Wolden, S.L., Souweidane, M.M., et al. (2016). Compartmental intrathecal radioimmunotherapy: results for treatment of metastatic CNS neuroblasticoma. J. Neurooncol. 97, 409–418.
21. Souweidane, M.M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzenico, P., Carrasquillo, J.A., Lyashchenko, S.K., Thakur, S.B., Donzelli, M., et al. (2018). Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation phase 1 trial. Lancet Oncol. 19, 1040–1050.
22. O’Rourke, D.M., Nasrallah, M.P., Desai, A., Melenhorst, J.J., Mansfield, K., Morrisette, J.J.D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaa9084.
23. Lichtman, E., Du, H.W., Savoldo, B., Ferrone, S., Li, G.M., Su, L.S., and Dotti, G. (2018). Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. Blood 132 (Suppl 1), 701, https://doi.org/10.1182/blood-2018-99-113468.
24. Guerry, T., Roumier, C., Berthon, C., Lepelley, P., Rennevillé, A., Nibouré, O., Dumery, F., Soenen, V., Roche, C., Preudhomme, C., and Quesnel, B. (2013). The B7-H3 Protein In Acute Myeloid Leukemia. Blood 122, 2620. V122.21.2620.2620.
25. Pope, M.E., Soste, M.V., Eyford, B.A., Anderson, N.L., and Pearson, T.W. (2009). Anti-peptide antibody screening: selection of high affinity monoclonal reagents by a refined surface plasmon resonance technique. J. Immunol. Methods 341, 86–96.
26. Gottschalk, S., Edwards, O.L., Sili, U., Huls, M.H., Goltssova, T., Davis, A.R., Heslop, H.E., and Rooney, C.M. (2003). Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101, 1905–1912.